Mary Burgess, MD
Infectious Disease · Little Rock, ARNPI 1407011968
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $623, 5.7 times the $110 reported in 2020.
Across 48 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$148
- Merck$147
- Viiv Healthcare Company$144
- Astellas Pharma US Inc$120
- Jazz Pharmaceuticals Inc.$110
- Shionogi Inc$92
- plus $254 from 7 others
Across 3 payments — averaging $15,008 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Celularity Inc.$45K
What the payments were for
- Food & beverage$93592%
- Education$808%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $148 |
| Merck | 8 | $147 |
| Viiv Healthcare Company | 8 | $144 |
| Astellas Pharma US Inc | 3 | $120 |
| Jazz Pharmaceuticals Inc. | 1 | $110 |
| Shionogi Inc | 5 | $92 |
| Aimmune Therapeutics, Inc. | 3 | $56 |
| Paratek Pharmaceuticals, Inc. | 3 | $53 |
| La Jolla Pharmaceutical Company | 3 | $51 |
| Insmed, Inc. | 3 | $46 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Gilead | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,015 in reported general payments places this provider in the 70th percentile of 36 infectious disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 85 | $341,932 |
| Daptomycin | 38 | $99,618 |
| DovatoDolutegravir Sodium/Lamivudine | 27 | $81,906 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 20 | $80,778 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 16 | $57,552 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 14 | $37,589 |
| Vancomycin Hcl | 64 | $11,299 |
| Cefepime Hcl | 29 | $10,659 |
| ErtapenemErtapenem Sodium | 18 | $10,573 |
| CeftriaxoneCeftriaxone Sodium | 53 | $5,392 |
| Meropenem | 19 | $5,278 |
| Cefazolin Sodium | 30 | $1,817 |
| Linezolid | 13 | $1,154 |
| Cefadroxil | 27 | $1,118 |
| Doxycycline Hyclate | 50 | $1,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $15 | $341,93285 claims |
| Viiv Healthcare CompanyDovato, Triumeq | $144 | $162,68447 claims |
| MerckDelstrigo | $147 | $37,58914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 36 infectious disease providers in Arkansas.
Other infectious disease in Little Rock
- Jeremy BariolaLittle Rock$2K
- Naveen PatilLittle Rock$1K
- Katherine FerrenLittle Rock$1K
- Priyenka ThapaLittle Rock$837
- Dwight LindleyLittle Rock$671
- Ryan DareLittle Rock$411
- Brandon WalserLittle Rock$219
- Jessica FrazierLittle Rock$164
- Matthew BurnsLittle Rock$135
- Rebekah ThompsonLittle Rock$123
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.